{"id":61829,"date":"2026-03-30T15:58:19","date_gmt":"2026-03-30T07:58:19","guid":{"rendered":"https:\/\/flcube.com\/?p=61829"},"modified":"2026-03-30T15:58:20","modified_gmt":"2026-03-30T07:58:20","slug":"sinovac-biotech-and-indonesias-bio-farma-forge-strategic-alliance-to-expand-vaccine-access-across-developing-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61829","title":{"rendered":"Sinovac Biotech and Indonesia\u2019s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets"},"content":{"rendered":"\n

Sinovac Biotech Ltd.<\/strong> (NASDAQ: SVA<\/a>) announced the signing of a strategic cooperation memorandum<\/strong> with PT Bio Farma<\/strong>, Indonesia\u2019s state-owned vaccine manufacturer, launching a comprehensive partnership spanning product distribution, localized manufacturing, and joint R&D<\/strong>. The alliance marks a major step in Sinovac\u2019s Southeast Asia expansion, as Indonesia becomes the first Asia-Pacific market<\/strong> to launch its inactivated EV71 vaccine, Inlive\u00ae<\/strong>, while also approving Healive\u00ae (hepatitis A)<\/strong> and its live attenuated varicella vaccine<\/strong>\u2014products now recognized locally for safety and efficacy.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Collaboration Pillar<\/th>Key Activities<\/th><\/tr><\/thead>
Product Distribution<\/strong><\/td>Expanded access to Sinovac\u2019s portfolio via Bio Farma\u2019s national immunization network<\/td><\/tr>
Localized Projects<\/strong><\/td>Potential tech transfer and fill-finish operations in Indonesia to support regional supply resilience<\/td><\/tr>
Cooperative R&D<\/strong><\/td>Joint development of next-generation vaccines targeting regional infectious disease priorities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The initiative aligns with Indonesia\u2019s ongoing health system transformation<\/strong>, aiming to strengthen domestic biomanufacturing capacity and equitable vaccine access.<\/p>\n\n\n\n

Sinovac\u2019s Approved Portfolio in Indonesia<\/h2>\n\n\n\n
Vaccine<\/th>Type<\/th>Indication<\/th>Status<\/th><\/tr><\/thead>
Inlive\u00ae<\/strong><\/td>Inactivated EV71 vaccine<\/td>Hand, foot, and mouth disease (HFMD) prevention<\/td>First Asia-Pacific launch<\/strong><\/td><\/tr>
Healive\u00ae<\/strong><\/td>Inactivated hepatitis A vaccine<\/td>Hepatitis A prophylaxis<\/td>Approved, widely used<\/td><\/tr>
Varicella Vaccine<\/strong><\/td>Live attenuated<\/td>Chickenpox prevention<\/td>Approved, integrated into private sector programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

All three products have gained regulatory and clinical credibility<\/strong> among Indonesian healthcare providers and public health authorities.<\/p>\n\n\n\n

Strategic Endorsement from Indonesian Government<\/h2>\n\n\n\n

Budi Gunadi Sadikin<\/strong>, Indonesia\u2019s Minister of Health, emphasized that the collaboration should advance across three critical dimensions<\/strong>:<\/p>\n\n\n\n